UBS Group’s LakeShore Biopharma LSB Stock Holding History

UBS Group’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,469	Closed	-$6.6K	–	11105
2025 Q2	$6.6K	Buy	6,469 +5,469	+547%	+$6.87K	﹤0.01%	9080
2025 Q1	$2.45K	Buy	1,000 +60	+6%	+$148	﹤0.01%	9330
2024 Q4	$3.25K	Sell	940 -4,002	-81%	-$11.7K	﹤0.01%	8904
2024 Q3	$33.7K	Buy	+4,942	New	+$25.6K	﹤0.01%	7063
2023 Q3	–	Sell	-705	Closed	-$9.73K	–	10055
2023 Q2	$9.73K	Buy	+705	New	+$10.4K	﹤0.01%	7168

Other funds holding LSB

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group's LSB Position: Q3 2025 in Review

UBS Group sold out of LakeShore Biopharma (LSB) in Q3 2025, closing a stake of 6,469 shares — an estimated $6.6K sold.

UBS Group first reported a position in LSB in Q2 2023 and held it in 5 quarters. The position peaked at $33.7K in Q3 2024. 1 fund tracked by Wall St. Rank holds LSB as of Q3 2025.

UBS Group reported no remaining LakeShore Biopharma position as of Q3 2025 after selling out during the quarter.
UBS Group sold 6,469 LakeShore Biopharma shares in Q3 2025, an estimated $6.6K.
UBS Group first reported a position in LakeShore Biopharma in Q2 2023 and held it in 5 quarters.
UBS Group's LakeShore Biopharma position peaked at $33.7K in Q3 2024.
1 fund tracked by Wall St. Rank held LakeShore Biopharma as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.